Kornimate/medical-research-clean huggingface dataset:
serological autoantibodies in early kidney cancer diagnosis and prognosis: a multicenter study

Conditions: Renal Carcinoma; Serology; Autoantibody Profile

Summary: this project aims to construct a multicenter retrospective study by retrospectively collecting clinical, serological, and pathological data from patients. a comprehensive data management system will be established to facilitate the integration and analysis of multicenter data, alongside antibody profiling characteristics. a predictive model based on serological autoantibody profiles will be developed and validated using both internal and external cohorts. this model will predict clinical prognostic factors in renal carcinoma and identify patient populations likely to respond to immunotherapy. by enabling personalized treatment decisions and minimizing unnecessary treatment risks, the model aims to improve patient quality of life and overall prognosis.


Eligibility criteria:
inclusion criteria: * pathological diagnosis of ccrcc; * availability of complete clinical, pathological, and follow-up data; * sufficient preoperative serum available for collection; * well-preserved pathological slides for subsequent immunohistochemical (chip) analysis; * at least one post-treatment follow-up/efficacy evaluation. exclusion criteria: * therapeutic contraindication cohort: individuals presenting with severe comorbidities rendering them medically ineligible for therapeutic interventions; * oncological multiplicity: subjects with either (a) antecedent therapeutic regimens targeting non-index malignancies or (b) concurrent diagnosis of untreated active malignancies; * biospecimen integrity violation: cases demonstrating serum hemolysis or compromised specimen integrity; * data insufficiency cohort: patients exhibiting incomplete clinical/pathological records or insufficient longitudinal follow-up data for comprehensive analysis.

Keywords: renal carcinoma autoantibody profile serology
a phase 2 study of ssgj-707 in metastatic colorectal cancer patients

Conditions: Metastatic Colorectal Cancer

Summary: this study includes two parts:part 1: ssgj-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.part 2: ssgj-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.


Eligibility criteria:
inclusion criteria: 1. males and/or females over age 18 2. histologically and/or cytologically documented metastatic colorectal cancer confirmed . 3. eastern cooperative oncology group (ecog) performance status of 0-1. 4. expected survival \>=12 weeks. 5. signed informed consent form. exclusion criteria: 1. known uncontrolled or symptomatic central nervous system metastatic disease. 2. adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (national cancer institute common terminology criteria \[nci ctcae\] v.5.0). 3. inadequate organ or bone marrow function. 4. pregnant or breast-feeding woman. 5. known allergies, hypersensitivity, or intolerance to ssgj-707 the above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Keywords: ssgj-707 colorectal cancer
association between rvt and prognosis after neoadjuvant targeted therapy in egfr nsclc

Conditions: Lung Cancer (NSCLC)

Summary: egfr-mutated nsclc is a distinct subtype that responds well to targeted therapies. neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (rvt) remains unclear. this retrospective study examines the association between rvt and survival outcomes. the findings will further validate the importance of rvt as a surrogate.

non-small cell lung cancer (nsclc) with egfr mutations represents a molecularly distinct subset of lung cancer that benefits from targeted therapies. neoadjuvant targeted therapy has emerged as a promising approach for locally advanced nsclc, aiming to achieve tumor downstaging and improve surgical outcomes. however, the prognostic significance of residual viable tumor (rvt) after neoadjuvant targeted therapy remains poorly understood. this retrospective study investigates the association between the percentage of rvt and survival outcomes in egfr-mutated nsclc patients following neoadjuvant targeted therapy. specific survival outcomes were disease-free survival (dfs) and event-free survival (efs). by highlighting rvt as a critical prognostic biomarker, the findings provide actionable insights for optimizing postoperative management and stratifying high-risk patients. this work underscores the need for pathological evaluation of rvt to refine prognosis and treatment strategies.

Eligibility criteria:
inclusion criteria: * age 18-80 years old; * pathologically diagnosed egfr-mutated non-small cell lung cancer (nsclc); * treated with neoadjuvant targeted therapy; * undergoing definitive surgery. exclusion criteria: * a history of prior chemotherapy, immunotherapy, or radiotherapy. * a history of malignancy or lung surgery; * missing key data.

Keywords: lung cancer neoadjuvant targeted therapy residual viable tumor prognosis egfr-mutated
cardiologist trial: artificial intelligence enabled electrocardiogram for atrial fibrillation detection

Conditions: Atrial Fibrillation New Onset

Summary: this is a randomized controlled trial (rct) to test a novel artificial intelligence (ai)-enabled electrocardiogram (ecg)-based screening tool for improving the diagnosis and management of atrial fibrillation.


Eligibility criteria:
inclusion criteria: * patients in emergency department or inpatient department * patients had at least 1 ecg * patients cared by non-cardiologist exclusion criteria: * patients without history of atrial fibrillation diagnosis. * patients without history of long-term noac or warfarin usage. * patients without history of hemorrhagic stoke or ishemic stroke. * patients with low egfr (\<30 ml/min)
the effect of night eye mask on post-operative pain in cardiac surgery patients

Conditions: Sleep Deprivation; Postoperative Pain

Summary: environmental factors such as noise and light have been cited as important causes of sleep deprivation in intensive care unit (icu) patients. previous studies demonstrated a hyperalgesic alteration in pain perception following a controlled sleep deprivation protocol. another studies indicated that using eye masks can improve rem sleep in healthy subjects in simulated icu environment, and improve sleep quality in icu patients. this study aimed to determine the effects of using eye masks on sleep and thus on pain quality in postoperative cardiac surgery patients in icu.


Eligibility criteria:
inclusion criteria: * (1) age ≧18 years; (2) no history of neurological or psychiatric disorders; (3) ability of patients to communicate verbally and understand the sleep questionnaires administered in the icu; (3) length of icu stay ≥48 hours; (4) glasgow coma score (gcs) \>8 in the first to third day. postoperative extubation of mv within few hour (before the time of 9 pm for postoperative patients. exclusion criteria: * patients over age 65 were excluded from the study because of potential age-related differences in sleep. patients reporting frequent nighttime awakenings, snoring, or chronic use of benzodiazepines or opioids were excluded because of potential confounding influences of these factors on postoperative sleep, pain, or opioid requirement.
out-of-hospital randomized comparison of video-assisted endotracheal intubation

Conditions: Intubation Intratracheal; Airway Management; Emergency Treatment

Summary: this research project examines the effectiveness of different video laryngoscopes in a out-of-hospital emergency intubation. since in preclinical airway management severe incidents with esophageal failures of intubation may partly happen or rather endotracheal intubation may completely fail, it is of great importance to evaluate alternative ways of endotracheal intubation in out-of-hospital emergency medicine. video laryngoscopy has been proven in everyday clinical practice and may clinically be superior in most situations when compared to endotracheal intubation using a conventional laryngoscope. no data exist, if different video laryngoscope types perform differently in the out-of-hospital setting. the investigators hypothesize that there would be no difference with regard to intubation time, intubation success, and intubation morbidity between different models of video laryngoscopes.


Eligibility criteria:
inclusion criteria: - all adult emergency patients, age 18 years and older for whom a preclinical emergency intubation is necessary exclusion criteria: * age under 18 years * laryngoscopy according to the algorithm of airway management not being indicated

Keywords: out-of-hospital airway management intubation video laryngoscope
impact of laxative therapy with lactulose in the evolution of organ dysfunction in critically ill patients.

Conditions: Constipation

Summary: main features of the study: therapeutic intervention. constipation is a frequent complication in critical ill patients. the disaccharide lactulose has a laxative osmotic activity. given the scant evidence and the potential risk associated with constipation in seriously ill patients, this study aims to assess the impact of laxative therapy in the prognosis of critically ill patients. study hypothesis: constipation is part of the clinical spectrum of intestinal dysfunction and if treated can result in improved prognosis for critically ill patients.

objectives: evaluate the impact of daily laxative therapy in the prognosis of critically ill patients through the evaluation of organ failure by the sequential organ failure score assessment (sofa). will also be evaluated morbidity data, namely incidence of bloodstream infection, pneumonia and severe sepsis, days free of mechanical ventilation, length of hospital stay, icu and hospital mortality. the study will be conducted in two intensive care units of hospital sao paulo, unifesp. inclusion criteria: patients who are mechanically ventilated, with prediction to stay in the icu for more than three days and getting at least 20% of full nutritional support in the form of enteral nutrition. patients will be randomized into two groups: group 1 - patients treated according to medical prescription. group 2 - patients will receive lactulone in order to evacuate daily. the patient included in the intervention group will receive latulose 30 ml of 8 in 8 hours. patients will be monitored, adjusted doses and procedures, if necessary. it is intended to include 44 patients per group.

Eligibility criteria:
inclusion criteria: * icu patients expected to stay for 3 more days, on mechanical ventilation and receiving at least 20% of calculated nutrient intake enterally. exclusion criteria: * younger than 18 years, * pregnancy, * contraindication to enteral nutrition, * patients with liver disease, * contraindications to the use of lactulose, * patients with poor prognosis or without full therapeutic indication investment, * presence of colostomy or ileostomy, * intestinal diseases, * such as disease crohn's, * ulcerative colitis, * short bowel syndrome.

Keywords: critically ill patients intestinal failure
ap-011 study to evaluate the safety of a single intra-articular injection of ampion™ for arthritis of the basal thumb joint

Conditions: Osteoarthritis of the Hand

Summary: this study will evaluate the safety of an intra-articular injection of ampion™ in adults with pain due to osteoarthritis of the basal thumb joint.

a prospective phase i study to evaluate the safety of a single intra-articular injection of ampion™ as a treatment for arthritis of the basal thumb joint. primary objective is: to evaluate the safety of ampion™ (up to 3 ml) in comparison to saline placebo (up to 3 ml) when injected into the basal thumb joint.

Eligibility criteria:
inclusion criteria: 1. able to provide written informed consent to participate in the study. 2. willing and able to comply with all study requirements and instructions of the site study staff. 3. male or female, 40 years to 85 years old (inclusive). 4. radiographic evidence of basal joint arthritis (eaton-littler classification, stages 1 through 4). 5. pain associated with basal joint arthritis, defined as a score ≥ 4 as evaluated by the australian-canadian oa index (auscan)-numeric rating score (nrs, 0-10). exclusion criteria: 1. as a result of medical review and screening investigation, the principal investigator considers the subject unfit for the study. 2. previous ampion™ injection. 3. a history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion). 4. a history of allergic reactions to excipients in 5% human albumin (n-acetyltryptophan, sodium caprylate). 5. women who are currently pregnant or who could become pregnant. 6. inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis, as assessed locally by the principal investigator. 7. any other disease or condition interfering with the free use and evaluation of the index thumb for the duration of the trial (e.g., congenital defects, stricture). 8. major injury to the index thumb within the 12 months prior to screening. 9. any pharmacological or non-pharmacological treatment targeting oa started or changed during the 4 weeks prior to treatment or likely to be changed during the duration of the study. 10. use of the following medications are exclusionary: * ia injected pain medications in the study thumb during the study; * analgesics containing opioids; * nsaids (including but not limited to ibuprofen, aspirin, naproxen, diclofenac) acetaminophen is available as a rescue medication during the study from the provided supply; * topical prescription treatment on osteoarthritis index thumb during the study; * significant anticoagulant therapy (e.g., heparin or lovenox) during the study (treatment such as aspirin in the cardio-protective dose (81mg) and plavix are allowed); * systemic treatments that may interfere with safety or efficacy assessments during the study; * immunosuppressants; * use of corticosteroids \> 10 mg prednisolone equivalent per day (if ≤ 10 mg prednisolone, the dose must be stable, defined as chronic use of the same dose for at least 1 month). 11. any human albumin treatment in the 3 months before randomization.
observational study of disease severity in participants diagnosed with crohn's disease and long term impact of treatment strategies in participants with moderate to severe crohn's disease (protocol p06484)

Conditions: Crohn Disease

Summary: this is an observational study to determine the prevalence of moderate to severe crohn's disease (cd) among patients with active cd and to evaluate existing therapeutic trends in a standard clinical practice.


Eligibility criteria:
inclusion criteria 1. must have a diagnosis of active crohn's disease irrespective of severity, 2. must be inadequately controlled with their current therapy and for whom physician decides to switch treatment. 3. must be between 18 and 65 years of age, of either sex, 4. must demonstrate willingness to participate in the study by signing the written informed consent. exclusion criteria * no specific exclusion criteria will be applied to a participant as long as the participant is eligible for the trial

Keywords: crohn's disease standard-of-care crohn disease active crohn's disease
human papillomavirus (hpv) self-sampling as a test of cure after treatment of cervical intra-epithelial neoplasia

Conditions: Cervical Intra-epithelial Neoplasia Grade 1 or Worse

Summary: the purpose of this study is to evaluate the performance of hpv self-sampling (self-hpv) in detecting residual/recurrent disease in women treated by loop electro-surgical excision (leep) for cin1+.

the hpv test is an efficient method to assess the long-term risk of residual/recurrent disease in women treated for cervical intraepithelial neoplasia grade 1 or worse (cin1+). women treated by leep for cin1+ will be invited to participate. follow-up visits will be performed at 6 months and 12 months after treatment and will include cytology, colposcopy when indicated and hpv testing. two weeks before each follow-up visit at the colposcopy clinic, a home-based self-hpv will be organized. a sample of 168 women will be included. agreement between the two methods (dr-hpv vs. s-hpv) will be measured using the kappa statistic (κ). the investigators expect to find that self-hpv may be an accurate method to predict residual and recurrent disease in women previously treated by leep.

Eligibility criteria:
inclusion criteria: * attending colposcopy clinic * biopsy-proven cin1+ lesion * understands study procedures and accepts voluntarily to participate by signing the informed consent form exclusion criteria: * pregnancy
non-positive pressure ventilation in hypoxemic patients

Conditions: Acute Respiratory Failure

Summary: the study is aimed to assess the possible benefit of non-positive pressure mechanical support in front of conventional ventilation in patients admitted to the intensive care unit (icu) because of pure hypoxemic respiratory failure.

pure hypoxemic patients admitted to intensive care unit in a teaching hospital have been randomized to be treated by conventional ventilatory support or non-positive mechanical ventilation support. those patients who did not benefit from the experimental non-positive ventilatory support, were intubated and conventionally mechanically ventilated and discarded for analysis. the primary outcome was mortality rate in both groups, and secondary outcomes were length of stay, improvement of oxygenation, and reduced complications rates.

Eligibility criteria:
inclusion criteria: * dyspnea with respiratory rates higher than 35 p.m. * po2 \< 65 mmhg * pao2/fio2 \< 250 exclusion criteria: * respiratory or cardiac arrest * gastrointestinal bleeding * hemodynamic instability * face surgery * upper airway obstruction * inability for active cooperation * need for airway protection * exacerbation of copd * decrease of conscious level * acute pulmonary cardiogenic oedema
study of tocilizumab (roactemre) administered subcutaneously in participants with rheumatoid arthritis in everyday clinical practice

Conditions: Rheumatoid Arthritis

Summary: arata is a prospective, non-interventional, multicenter, observational study in germany to evaluate the long-term effectiveness and tolerability of subcutaneously administered tocilizumab in participants with rheumatoid arthritis in daily clinical practice. participants will be followed over an observation period of up to 2 years after the initial injection.


Eligibility criteria:
inclusion criteria: * participants who have not yet been treated with tocilizumab * participants who have received the first injection with tocilizumab maximum 1 month before inclusion in the study and the necessary baseline data and disease characteristics are present exclusion criteria: * participants who at the time of the study inclusion are participating in a different interventional study on rheumatoid arthritis
gr defect in sputum cells in copd

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: to investigate a possible mechanism of the gr defect in patients with severe copd by studying the effect of dexamethasone (dex) on gr-gre binding, expression of inflammatory and anti-inflammatory factors such as il-6, il-8, mkp-1, gilz, slpi production in sputum cells


Eligibility criteria:
inclusion criteria: * patients with moderate (stage ii, gold) copd or subjects who are healthy smokers or subjects who are non-smokers. * written informed consent exclusion criteria: * current upper respiratory tract infections * any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study * subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason
criteria of extubation failure of brain injured patients. elaboration of a prognostic score.

Conditions: Brain Injury

Summary: identification of criteria associated with extubation failure of brain injured patients. elaboration of a prognostic score of extubation failure of brain injured patients.

prospective clinical study in icu with brain injured ventilated patients eligible to extubation. identification of clinical and biological criteria associated with failure of extubation. elaboration of a prognostic score of extubation failure of brain injured patients, based on criteria previously identified with multivariate analysis. failure of extubation is defined by the need of re-intubation or the need for non-invasive ventilation within 48 hours or more after extubation.

Eligibility criteria:
inclusion criteria: * adult brain injured patients ventilated eligible to discontinuation of mechanical ventilation * stable respiratory and hemodynamic conditions * ventilated patients for more than 48 hours * adequate gaseous exchange (spo2 ≥ 92% and respiratory rate ≤ 35/min, fio2 ≤ 40%, positive end-expiratory pressure ≤ 5 cmh2o, pressure support ≤ 8 cmh2o, tidal volume ≥ 7ml/kg * therapeutic extubation exclusion criteria: * • status epilepticus * cerebrospinal infection * patients under 15 years old * mechanical ventilation of \< 48 h * spinal cord injury * withdrawal of life support

Keywords: critical care brain injured patients mechanical ventilation weaning extubation prognostic score clinical examination